Insulin lispro
Clinical data | |
---|---|
Trade names | Humalog, Liprolog, Admelog, others |
Other names | URLi, LY900014, LY-275585, insulin lispro-aabc |
AHFS/Drugs.com | Monograph |
MedlinePlus | a697021 |
License data | |
Pregnancy category |
|
Subcutaneous | |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
JSmol) | |
| |
| |
(what is this?) (verify) |
Insulin lispro, sold under the brand name Humalog among others, is a
Common side effects include
Insulin lispro was first approved for use in the United States in 1996.[3][6][7] It is a manufactured analogue of human insulin where two amino acids have swapped positions.[8] In 2021, it was the 55th most commonly prescribed medication in the United States, with more than 12 million prescriptions.[9][10]
Medical uses
Insulin lispro is used to treat people with type 1 diabetes or type 2 diabetes.[3] People doing well on short-acting insulin should not routinely be changed to insulin lispro, but may benefit from some advantages like flexibility and responsiveness.[3]
Side effects
Common
Mechanism of action
Through
Chemistry
It is a manufactured form of human insulin where the amino acids lysine and proline have been switched at the end of the B chain of the insulin molecule.[8] This switch of amino acids mimics Insulin-like growth factor 1 which also has lysine (K) and proline (P) in that order at positions 28 and 29.[12]
History
Insulin lispro (brand name Humalog) was granted marketing authorization in the European Union in April 1996,[13] and it was approved for use in the United States in June 1996.[7][14]
Insulin lispro (brand name Liprolog) was granted marketing authorization in the European Union in May 1997,[15] and again in August 2001.[16]
Combination drugs combining insulin lispro and other forms of insulin were approved for use in the United States in December 1999.[17][18][19]
Insulin lispro Sanofi was granted marketing authorization as a biosimilar in the European Union in July 2017.[20]
Insulin lispro injection (brand name Admelog) was approved for use in the United States in December 2017.[21][22][23]
In January 2020, the
Society and culture
Economics
In the United States, the price of for a vial of Humalog increased from US$35 in 2001 to $234 in 2015,[27] or $10.06 and $29.36 per 100 units.[28] In April 2019, Eli Lilly and Company announced they would produce a version selling for $137.35 per vial.[27] The chief executive said that this was a contribution "to fix the problem of high out-of-pocket costs for Americans living with chronic conditions", but Patients for Affordable Drugs Now said it was just a public relations move, as "other countries pay $20 for a vial of insulin."[27] In March 2023, Lilly announced a program capping their insulin prices at $35 per month.[29]
References
- ^ "Insulin lispro Use During Pregnancy". Drugs.com. 7 October 2019. Retrieved 23 February 2020.
- ^ "Humalog 100 units/ml, solution for injection in vial - Summary of Product Characteristics (SmPC)". (emc). 30 January 2020. Retrieved 23 February 2020.
- ^ a b c d e f g h i j "Insulin Lispro Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 3 March 2019.
- ISBN 9780857113382.
- ^ "Insulin lispro Pregnancy and Breastfeeding Warnings". Drugs.com. Retrieved 3 March 2019.
- ^ a b c "Humalog- insulin lispro injection, solution Humalog Kwikpen- insulin lispro injection, solution Humalog Junior Kwikpen- insulin lispro injection, solution Humalog Tempo Pen- insulin lispro injection, solution". DailyMed. 25 November 2019. Retrieved 23 February 2020.
- ^ a b "Humalog approval" (PDF). U.S. Food and Drug Administration (FDA). 14 June 1996. Retrieved 23 February 2020.
- ^ PMID 9677011.
- ^ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
- ^ "Insulin Lispro - Drug Usage Statistics". ClinCalc. Retrieved 14 January 2024.
- PMID 9456992. Archived from the originalon 29 September 2007. Retrieved 5 September 2007.
- ^ Ratledge, C., & Kristiansen, B. (2007). Basic biotechnology. Cambridge: Cambridge University Press. Page 513 "insulin lispro, where, in analogy to the naturally occur- ring insulin homologue insulin-like growth factor-I (IGF-I), the order of the amino acid residues B28 and B29 was changed;"
- ^ "Humalog EPAR". European Medicines Agency (EMA). 11 February 2020. Retrieved 23 February 2020.
- ^ "Humalog: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 23 February 2020.
- ^ "Liprolog EPAR". European Medicines Agency (EMA). 1 August 2001. Retrieved 23 February 2020.
- ^ "Liprolog EPAR". European Medicines Agency (EMA). 11 February 2020. Retrieved 23 February 2020.
- ^ "Drug Approval Package: Humalog Mix (75/25 & 50/50) NDA# 21-017 & 21-018". U.S. Food and Drug Administration (FDA). 24 December 1999. Retrieved 23 February 2020.
- ^ "Humalog Mix50/50- insulin lispro injection, suspension Humalog Mix50/50 Kwikpen- insulin lispro injection, suspension". DailyMed. 19 November 2019. Retrieved 23 February 2020.
- ^ "Humalog Mix75/25- insulin lispro injection, suspension Humalog Mix75/25 Kwikpen- insulin lispro injection, suspension". DailyMed. 3 February 2020. Retrieved 23 February 2020.
- ^ "Insulin lispro Sanofi EPAR". European Medicines Agency (EMA). 17 June 2019. Retrieved 23 February 2020.
- ^ "Drug Approval Package: Admelog (insulin lispro)". U.S. Food and Drug Administration (FDA). 17 May 2018. Retrieved 23 February 2020.
- ^ "FDA Approves Sanofi's Admelog (insulin lispro injection) - Dec 11, 2017". Sanofi (Press release). 11 December 2017. Retrieved 23 February 2020.
- ^ "FDA approves Admelog, the first short-acting "follow-on" insulin product to treat diabetes". U.S. Food and Drug Administration (FDA) (Press release). 11 December 2017. Retrieved 12 December 2017.
- ^ "Lyumjev: Pending EC decision". European Medicines Agency (EMA). 30 January 2020. Archived from the original on 31 January 2020. Retrieved 23 February 2020.
- ^ "CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes". Eli Lilly and Company (Press release). 31 January 2020. Retrieved 23 February 2020.
- ^ "Ljumjev EPAR". European Medicines Agency (EMA). 29 January 2020. Retrieved 16 April 2020.
- ^ a b c Sullivan, Peter (3 April 2019). "Drug company announces new version of insulin at half the price". The Hill. Retrieved 15 April 2019.
- ^ Langreth R (29 June 2016). "Decoding Big Pharma's Secret Drug Pricing Practices". Bloomberg. Retrieved 15 July 2016.
- ^ "Lilly Cuts Insulin Prices by 70% and Caps Patient Insulin Out-of-Pocket Costs at $35 Per Month". Eli Lilly and Company (Press release). 1 March 2023. Retrieved 14 April 2023.